Tallal Younis
Research Subjects
Tallal Younis has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
D. Rayson
Department of Medicine at Dalhousie University and the Atlantic Clinical Cancer Research Unit (ACCRU) at the Queen Elizabeth II Health Sciences Centre, 1276 South Park Street, Halifax, NS, B3H 2Y9, Canada
7 shared publicationsC. Skedgel
Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, U.K.
6 shared publicationsK. Thompson
2 shared publicationsM. Sellon
2 shared publicationsP. J. Barnes
2 shared publications- A. Rundle
Dalhousie University
1 shared publication
Latest Publications
- Open Access
- 5 June 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2107-2114
Nurse Navigators’ Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer
Coordinating breast cancer treatment is a complex task that can overwhelm patients and their support networks. Though the Cancer Patient Navigator (CPN) program in Nova Scotia (NS) provides professional assistance to patients, certain groups of patients may still face barriers to accessing its services. Employing interviews and a modified Delphi approach with CPN participants, this study sought to identify factors associated with the need for navigation to help better target CPN program referrals among breast cancer patients. Six CPNs were recruited directly through the CPN program manager for interviews and surveys. The CPNs identified 27 different factors, which were divided into 4 categories: sociodemographic, psychological, clinical and health systems. While these patient factors (particularly sociodemographic) are not directly modifiable, awareness of their association with the need for navigation could be used to better target patients with a high need for navigation for referral to CPN services.
- 5 June 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2107-2114
Open AccessNurse Navigators’ Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer
Coordinating breast cancer treatment is a complex task that can overwhelm patients and their support networks. Though the Cancer Patient Navigator (CPN) program in Nova Scotia (NS) provides professional assistance to patients, certain groups of patients may still face barriers to accessing its services. Employing interviews and a modified Delphi approach with CPN participants, this study sought to identify factors associated with the need for navigation to help better target CPN program referrals among breast cancer patients. Six CPNs were recruited directly through the CPN program manager for interviews and surveys. The CPNs identified 27 different factors, which were divided into 4 categories: sociodemographic, psychological, clinical and health systems. While these patient factors (particularly sociodemographic) are not directly modifiable, awareness of their association with the need for navigation could be used to better target patients with a high need for navigation for referral to CPN services.
- Open Access
- 1 June 2020
- Published by MDPI AG in Current Oncology
- Vol. 27 (3) , E336-E342
Women's views about breast cancer prevention at mammography screening units and well women's clinics
Background Women attending mammography screening units (Msus) and well women's clinics (wwcs) represent a motivated cohort likely to engage in interventions aimed at primary breast cancer (Bca) prevention. Methods We used a feasibility questionnaire distributed to women (40-49 or 50-74 years of age) attending msus and wwcs in Halifax, Nova Scotia, to examine women's views about Bca primary prevention and sources of health care information, prevalence of lifestyle-related Bca risk factors, and predictors of prior mammography encounters within provincial screening guidelines. Variables examined included personal profiling, comorbidities, prior mammography uptake, lifestyle behaviours, socioeconomic status, health information sources, and willingness to discuss or implement lifestyle modifications, or endocrine therapy, or both. A logistic regression analysis examined associations with prior mammography encounters. Results Of the 244 responses obtained during 1.5 months from women aged 40-49 years (n = 75) and 50-74 years (n = 169), 56% and 75% respectively sought or would prefer to receive health information from within, as opposed to outside, health care. Lifestyle-related Bca risk factors were prevalent, and most women were willing to discuss or implement lifestyle modifications (93%) or endocrine therapy (67%). Of the two age groups, 49% and 93% respectively had previously undergone mammography within guidelines. Increasing age and marital status (single, separated, or divorced vs. married or partnered) were independent predictors of prior mammography encounters within guidelines for women 40-49 years of age; no independent predictors were observed in the older age group. Conclusions Women attending MSUS and wwcs seem to largely adhere to mammography guidelines and appear motivated to engage in Bca primary prevention strategies, including lifestyle modifications and endocrine therapy. Women's views as observed in this study provide a rationale for the potential incorporation of Bca risk assessment within the "mammogram point of care" to engage motivated women in BCa primary prevention strategies.
- 1 June 2020
- Published by MDPI AG in Current Oncology
- Vol. 27 (3) , E336-E342
Open AccessWomen's views about breast cancer prevention at mammography screening units and well women's clinics
Background Women attending mammography screening units (Msus) and well women's clinics (wwcs) represent a motivated cohort likely to engage in interventions aimed at primary breast cancer (Bca) prevention. Methods We used a feasibility questionnaire distributed to women (40-49 or 50-74 years of age) attending msus and wwcs in Halifax, Nova Scotia, to examine women's views about Bca primary prevention and sources of health care information, prevalence of lifestyle-related Bca risk factors, and predictors of prior mammography encounters within provincial screening guidelines. Variables examined included personal profiling, comorbidities, prior mammography uptake, lifestyle behaviours, socioeconomic status, health information sources, and willingness to discuss or implement lifestyle modifications, or endocrine therapy, or both. A logistic regression analysis examined associations with prior mammography encounters. Results Of the 244 responses obtained during 1.5 months from women aged 40-49 years (n = 75) and 50-74 years (n = 169), 56% and 75% respectively sought or would prefer to receive health information from within, as opposed to outside, health care. Lifestyle-related Bca risk factors were prevalent, and most women were willing to discuss or implement lifestyle modifications (93%) or endocrine therapy (67%). Of the two age groups, 49% and 93% respectively had previously undergone mammography within guidelines. Increasing age and marital status (single, separated, or divorced vs. married or partnered) were independent predictors of prior mammography encounters within guidelines for women 40-49 years of age; no independent predictors were observed in the older age group. Conclusions Women attending MSUS and wwcs seem to largely adhere to mammography guidelines and appear motivated to engage in Bca primary prevention strategies, including lifestyle modifications and endocrine therapy. Women's views as observed in this study provide a rationale for the potential incorporation of Bca risk assessment within the "mammogram point of care" to engage motivated women in BCa primary prevention strategies.
- Open Access
- 13 December 2018
- Published by Springer Nature in Breast Cancer Research
- Vol. 20 (1) , 1-14
ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth
The ability of solid tumor cells to resist anoikis, apoptosis triggered by cell detachment from the extracellular matrix (ECM), is thought to be critical for 3D tumor growth. ErbB2/Her2 oncoprotein is often overproduced by breast tumor cells and blocks their anoikis by partially understood mechanisms. In our effort to understand them better, we observed that detachment of nonmalignant human breast epithelial cells from the ECM upregulates the transcription factor Irf6. Irf6 is thought to play an important role in mammary gland homeostasis and causes apoptosis by unknown mechanisms. We noticed that ErbB2, when overproduced by detached breast epithelial cells, downregulates Irf6. To test whether ErbB2 downregulates Irf6 in human ErbB2-positive breast cancer cells, we examined the effect of ErbB2 inhibitors, such as the anti-ErbB2 antibody trastuzumab or the ErbB2/epidermal growth factor receptor small-molecule inhibitor lapatinib, on Irf6 in these cells. Moreover, we performed Irf6 IHC analysis of tumor samples derived from the locally advanced ErbB2-positive breast cancers before and after neoadjuvant trastuzumab-based therapies. To examine the role of Irf6 in anoikis of nonmalignant and ErbB2-overproducing breast epithelial cells, we studied anoikis after knocking down Irf6 in the former cells by RNA interference and after overproducing Irf6 in the latter cells. To examine the mechanisms by which cell detachment and ErbB2 control Irf6 expression in breast epithelial cells, we tested the effects of genetic and pharmacological inhibitors of the known ErbB2-dependent signaling pathways on Irf6 in these cells. We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors. We found that detachment-induced Irf6 upregulation in nonmalignant breast epithelial cells requires the presence of the transcription factor ∆Np63α and that Irf6 mediates their anoikis. We showed that ErbB2 blocks Irf6 upregulation in ErbB2-overproducing cells by activating the mitogen-activated protein kinases that inhibit ∆Np63α-dependent signals required for Irf6 upregulation. Finally, we demonstrated that ErbB2-driven Irf6 downregulation in ErbB2-overproducing breast epithelial cells blocks their anoikis and promotes their anchorage-independent growth. We have demonstrated that ErbB2 blocks anoikis of breast epithelial cells by downregulating Irf6.
- 13 December 2018
- Published by Springer Nature in Breast Cancer Research
- Vol. 20 (1) , 1-14
Open AccessErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth
The ability of solid tumor cells to resist anoikis, apoptosis triggered by cell detachment from the extracellular matrix (ECM), is thought to be critical for 3D tumor growth. ErbB2/Her2 oncoprotein is often overproduced by breast tumor cells and blocks their anoikis by partially understood mechanisms. In our effort to understand them better, we observed that detachment of nonmalignant human breast epithelial cells from the ECM upregulates the transcription factor Irf6. Irf6 is thought to play an important role in mammary gland homeostasis and causes apoptosis by unknown mechanisms. We noticed that ErbB2, when overproduced by detached breast epithelial cells, downregulates Irf6. To test whether ErbB2 downregulates Irf6 in human ErbB2-positive breast cancer cells, we examined the effect of ErbB2 inhibitors, such as the anti-ErbB2 antibody trastuzumab or the ErbB2/epidermal growth factor receptor small-molecule inhibitor lapatinib, on Irf6 in these cells. Moreover, we performed Irf6 IHC analysis of tumor samples derived from the locally advanced ErbB2-positive breast cancers before and after neoadjuvant trastuzumab-based therapies. To examine the role of Irf6 in anoikis of nonmalignant and ErbB2-overproducing breast epithelial cells, we studied anoikis after knocking down Irf6 in the former cells by RNA interference and after overproducing Irf6 in the latter cells. To examine the mechanisms by which cell detachment and ErbB2 control Irf6 expression in breast epithelial cells, we tested the effects of genetic and pharmacological inhibitors of the known ErbB2-dependent signaling pathways on Irf6 in these cells. We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors. We found that detachment-induced Irf6 upregulation in nonmalignant breast epithelial cells requires the presence of the transcription factor ∆Np63α and that Irf6 mediates their anoikis. We showed that ErbB2 blocks Irf6 upregulation in ErbB2-overproducing cells by activating the mitogen-activated protein kinases that inhibit ∆Np63α-dependent signals required for Irf6 upregulation. Finally, we demonstrated that ErbB2-driven Irf6 downregulation in ErbB2-overproducing breast epithelial cells blocks their anoikis and promotes their anchorage-independent growth. We have demonstrated that ErbB2 blocks anoikis of breast epithelial cells by downregulating Irf6.
- Open Access
- 1 June 2018
- Published by MDPI AG in Current Oncology
- Vol. 25 (3) , 189-190
Oncology Education for Internal Medicine Residents: A Call for Action!
Oncology education for internal medicine residents: a call for action!
- 1 June 2018
- Published by MDPI AG in Current Oncology
- Vol. 25 (3) , 189-190
Open AccessOncology Education for Internal Medicine Residents: A Call for Action!
Oncology education for internal medicine residents: a call for action!
- Open Access
- 1 December 2017
- Published by MDPI AG in Current Oncology
- Vol. 24 (6) , 349-351
Evidence in Medicine: Math Versus Biology!
Evidence in medicine: math versus biology!
- 1 December 2017
- Published by MDPI AG in Current Oncology
- Vol. 24 (6) , 349-351
Open AccessEvidence in Medicine: Math Versus Biology!
Evidence in medicine: math versus biology!
- Open Access
- 1 October 2017
- Published by MDPI AG in Current Oncology
- Vol. 24 (5) , 279-281
Timeliness of the Oncology Drug Review Process for Public Funding in Canada
The oncology drug review process for public funding in Canada (Figure 1) encompasses both.
- 1 October 2017
- Published by MDPI AG in Current Oncology
- Vol. 24 (5) , 279-281
Open AccessTimeliness of the Oncology Drug Review Process for Public Funding in Canada
The oncology drug review process for public funding in Canada (Figure 1) encompasses both.
- 30 August 2016
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 159 (3) , 425-432
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its “value for money”. This systematic review examined (i) cost-effectiveness of PP versus SP, (ii) FN threshold at which PP is cost-effective including the guidelines 20 % threshold and (iii) potential impact of G-CSF efficacy assumptions on outcomes. The systematic review identified all cost-effectiveness/cost-utility analyses (CEA/CUA) involving PP versus SP G-CSF for AC in BC that met predefined inclusion/exclusion criteria. Five relevant CEA/CUA were identified. These CEA/CUA examined different AC regimens (TAC = 2; FEC-D = 1; TC = 2) and G-CSF formulations (filgrastim “F” = 4; pegfilgrastim “P” = 4) with varying baseline FN—risk (range 22–32 %), mortality (range 1.4–6.0 %) and utility (range 0.33–0.47). The potential G-CSF benefit, including FN risk reduction with P versus F, varied among models. Overall, relative to SP, PP was not associated with good value for money, as per commonly utilized CE thresholds, at the baseline FN rates examined, including the consensus 20 % FN threshold, in most of these studies. The value for money associated with PP versus SP was primarily dependent on G-CSF benefit assumptions including reduced FN mortality and improved BC survival. PP G-CSF for FN prevention in BC patients undergoing AC may not be a cost-effective strategy at the guidelines 20 % FN threshold.
- 30 August 2016
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 159 (3) , 425-432
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its “value for money”. This systematic review examined (i) cost-effectiveness of PP versus SP, (ii) FN threshold at which PP is cost-effective including the guidelines 20 % threshold and (iii) potential impact of G-CSF efficacy assumptions on outcomes. The systematic review identified all cost-effectiveness/cost-utility analyses (CEA/CUA) involving PP versus SP G-CSF for AC in BC that met predefined inclusion/exclusion criteria. Five relevant CEA/CUA were identified. These CEA/CUA examined different AC regimens (TAC = 2; FEC-D = 1; TC = 2) and G-CSF formulations (filgrastim “F” = 4; pegfilgrastim “P” = 4) with varying baseline FN—risk (range 22–32 %), mortality (range 1.4–6.0 %) and utility (range 0.33–0.47). The potential G-CSF benefit, including FN risk reduction with P versus F, varied among models. Overall, relative to SP, PP was not associated with good value for money, as per commonly utilized CE thresholds, at the baseline FN rates examined, including the consensus 20 % FN threshold, in most of these studies. The value for money associated with PP versus SP was primarily dependent on G-CSF benefit assumptions including reduced FN mortality and improved BC survival. PP G-CSF for FN prevention in BC patients undergoing AC may not be a cost-effective strategy at the guidelines 20 % FN threshold.
- 20 September 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (27) , 201
The potential economic impact of the 21-gene recurrence score: Guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.
201 Background: The 21-gene recurrence score (Oncotype DX: RS) appears to augment clinical-pathological prognostication and predicts adjuvant chemotherapy (chemo) benefits in patients with node-negative (N-) and node-positive (N+) hormone-receptor positive early-stage breast cancer. Economic analyses suggest that RS-guided chemo is a cost-effective strategy in N- breast cancer, but no evaluations were reported for N+ disease based on pre RS chemo utilization in clinical practice. We examined the cost-utility (CU) of a RS-guided chemo strategy, compared to current practice without RS in a population based cohort, in N- and N+ early-stage breast cancer. Methods: A generic state-transition model was developed to compute cumulative costs and quality-adjusted life years (QALY) over a 25-year horizon for patients with hormone-receptor positive early-stage breast cancer considered for chemo. We examined outcomes with and without chemo in RS-untested cohorts and in those with low, intermediate and high RS based on the reported prognostic and predictive impact of the RS. Chemo utilizations (current vs RS-guided), costs and utilities were derived from a Nova Scotia population based cohort, local resources and the literature. Sensitivity analyses were conducted for key model assumptions/parameters. Results: RS-guided chemo strategy is associated with incremental costs and QALY gains compared to chemo with no RS testing in both N- and N+ patients. The resultant CU ratios are $17,141/QALY and $5,772/QALY for N- and N+ disease, respectively. These CU ratios are well below commonly quoted thresholds and were most sensitive to RS-distribution, upfront chemo costs, chemo utilization rates and relative benefits of chemo in various RS-strata. Conclusions: RS-guided chemo in a population based cohort appears to be a cost-effective strategy, compared to chemo with no RS testing, in N- and N+ early-stage breast cancer.
- 20 September 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (27) , 201
The potential economic impact of the 21-gene recurrence score: Guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.
201 Background: The 21-gene recurrence score (Oncotype DX: RS) appears to augment clinical-pathological prognostication and predicts adjuvant chemotherapy (chemo) benefits in patients with node-negative (N-) and node-positive (N+) hormone-receptor positive early-stage breast cancer. Economic analyses suggest that RS-guided chemo is a cost-effective strategy in N- breast cancer, but no evaluations were reported for N+ disease based on pre RS chemo utilization in clinical practice. We examined the cost-utility (CU) of a RS-guided chemo strategy, compared to current practice without RS in a population based cohort, in N- and N+ early-stage breast cancer. Methods: A generic state-transition model was developed to compute cumulative costs and quality-adjusted life years (QALY) over a 25-year horizon for patients with hormone-receptor positive early-stage breast cancer considered for chemo. We examined outcomes with and without chemo in RS-untested cohorts and in those with low, intermediate and high RS based on the reported prognostic and predictive impact of the RS. Chemo utilizations (current vs RS-guided), costs and utilities were derived from a Nova Scotia population based cohort, local resources and the literature. Sensitivity analyses were conducted for key model assumptions/parameters. Results: RS-guided chemo strategy is associated with incremental costs and QALY gains compared to chemo with no RS testing in both N- and N+ patients. The resultant CU ratios are $17,141/QALY and $5,772/QALY for N- and N+ disease, respectively. These CU ratios are well below commonly quoted thresholds and were most sensitive to RS-distribution, upfront chemo costs, chemo utilization rates and relative benefits of chemo in various RS-strata. Conclusions: RS-guided chemo in a population based cohort appears to be a cost-effective strategy, compared to chemo with no RS testing, in N- and N+ early-stage breast cancer.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 6087
Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy.
6087 Background: Multigated acquisition (MUGA) scans are commonly employed to assess baseline cardiac function prior to adjuvant anthracycline-based chemotherapy and/or trastuzumab treatment in view of their potential cardiac toxicity. The aims of this population based study of Nova Scotia (NS) women with early-stage BC were: (1) determine current utilization patterns of MUGA scans in women with early-stage breast cancer and (2) examine impact of MUGA scans on choice of adjuvant chemotherapy (AdjC) regimen. Methods: All women diagnosed In NS, Canada with stage I-III BC between 10/2005- 09/2006 were identified through the provincial cancer registry. A retrospective chart review was performed to abstract all relevant clinical-pathological variables. The association between MUGA scan receipt and clinical-pathologic variables was examined through standard univariate and multivariate analyses. The influence of MUGA scan on AdjC regimen choice was examined through 2x2 tables and odds ratios. Results: The study included 593 women, of whom 238 received AdjC (94% anthracycline vs. 6% nonanthracycline). Overall, 198 women underwent baseline MUGA scans. Baseline MUGA scan receipt was associated with AdjC treatment (yes vs. no; p < 0.0001), HER2/neu status (positive vs. negative vs. not tested; p < 0.0001) and choice of AdjC regimen (anthracycline vs. nonanthracycline; p < 0.0001). All patients treated with adjuvant trastuzumab underwent serial MUGA scan testing. Abnormal MUGA defined as a left ventricular ejection fraction of < 50% was observed in 5/198 (2.5%). All 5 patients were smokers and 4 of these were > 50 years of age. In the one patient < 50 years with abnormal MUGA, subsequent echocardiograms indicated normal cardiac function. Conclusions: In this population-based study of women with early-stage BC, although the majority of patients considered for AdjC underwent baseline MUGA scan testing, the incidence of abnormal scans was low. Our results suggest that routine baseline MUGAs prior to finalizing a decision regarding AdjC is likely not required for the majority of asymptomatic patients not considered for trastuzumab therapy, particularly for those under the age of 50 who are nonsmokers. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 6087
Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy.
6087 Background: Multigated acquisition (MUGA) scans are commonly employed to assess baseline cardiac function prior to adjuvant anthracycline-based chemotherapy and/or trastuzumab treatment in view of their potential cardiac toxicity. The aims of this population based study of Nova Scotia (NS) women with early-stage BC were: (1) determine current utilization patterns of MUGA scans in women with early-stage breast cancer and (2) examine impact of MUGA scans on choice of adjuvant chemotherapy (AdjC) regimen. Methods: All women diagnosed In NS, Canada with stage I-III BC between 10/2005- 09/2006 were identified through the provincial cancer registry. A retrospective chart review was performed to abstract all relevant clinical-pathological variables. The association between MUGA scan receipt and clinical-pathologic variables was examined through standard univariate and multivariate analyses. The influence of MUGA scan on AdjC regimen choice was examined through 2x2 tables and odds ratios. Results: The study included 593 women, of whom 238 received AdjC (94% anthracycline vs. 6% nonanthracycline). Overall, 198 women underwent baseline MUGA scans. Baseline MUGA scan receipt was associated with AdjC treatment (yes vs. no; p < 0.0001), HER2/neu status (positive vs. negative vs. not tested; p < 0.0001) and choice of AdjC regimen (anthracycline vs. nonanthracycline; p < 0.0001). All patients treated with adjuvant trastuzumab underwent serial MUGA scan testing. Abnormal MUGA defined as a left ventricular ejection fraction of < 50% was observed in 5/198 (2.5%). All 5 patients were smokers and 4 of these were > 50 years of age. In the one patient < 50 years with abnormal MUGA, subsequent echocardiograms indicated normal cardiac function. Conclusions: In this population-based study of women with early-stage BC, although the majority of patients considered for AdjC underwent baseline MUGA scan testing, the incidence of abnormal scans was low. Our results suggest that routine baseline MUGAs prior to finalizing a decision regarding AdjC is likely not required for the majority of asymptomatic patients not considered for trastuzumab therapy, particularly for those under the age of 50 who are nonsmokers. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 6573
Accounting for improved outcomes in budget impact analyses: Adjuvant trastuzumab in HER2/neu-positive breast cancer
6573 Background: Adjuvant trastuzumab is associated with considerable acquisition costs, but it is important to consider net budget impact after accounting for improved outcomes. We estimated the net budget impact of adjuvant trastuzumab (aTZ) in early-stage HER2/neu-positive breast cancer from the perspective of the Canadian healthcare system. Methods: The budget impact analysis (BIA) built upon a cost-effectiveness model (Skedgel et al, ASCO 2007) that considered the costs of drug acquisition and delivery, cardiotoxicities and recurrent disease, as well as improved disease-free and overall survival outcomes derived from the HERA trial of aTZ vs. primary treatment alone, over a 5-year horizon. The BIA took a population-level approach based on estimated 2007 breast cancer incidence rates, population projections for 2007–2011 and estimated eligibility rates from our previous work (Drucker et al, ASCO 2006). All costs are reported in 2007 Canadian dollars (CDN$). Results: aTZ had an upfront cost of CDN$49,965 per patient, but reductions in cancer recurrence over the 5-year analysis horizon reduced the net cost to CDN$44,998 per patient. Net impact declined over the initial 5 years (2007- 2011) as savings due to recurrences avoided accrued (start-up phase) and the ratio of net to gross annual budget impact fell from 95% to 85%. The cumulative net impact over the initial 5-year period (2007–2011) was roughly 10% less than the gross impact based on acquisition costs alone. In the second 5-year period (2012–2016), net and gross budget impact increased with population growth and increasing incidence in an ageing population (‘steady-state’ phase). Net budget impact in 2007 was projected to be CDN$91.3 million. Budget impact was driven primarily by the aTZ eligibility rate (8.5% in the baseline analysis). Conclusions: Annual net budget impact declined over the start- up phase as upfront costs were offset in part by savings due to recurrences avoided. Net budget impact in the steady-state phase grew at the same rate as the gross impact, but started from a lower baseline. While the projected net budget impact of aTZ was substantial, this analysis demonstrates the importance of accounting for differences in outcomes when conducting BIA. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 6573
Accounting for improved outcomes in budget impact analyses: Adjuvant trastuzumab in HER2/neu-positive breast cancer
6573 Background: Adjuvant trastuzumab is associated with considerable acquisition costs, but it is important to consider net budget impact after accounting for improved outcomes. We estimated the net budget impact of adjuvant trastuzumab (aTZ) in early-stage HER2/neu-positive breast cancer from the perspective of the Canadian healthcare system. Methods: The budget impact analysis (BIA) built upon a cost-effectiveness model (Skedgel et al, ASCO 2007) that considered the costs of drug acquisition and delivery, cardiotoxicities and recurrent disease, as well as improved disease-free and overall survival outcomes derived from the HERA trial of aTZ vs. primary treatment alone, over a 5-year horizon. The BIA took a population-level approach based on estimated 2007 breast cancer incidence rates, population projections for 2007–2011 and estimated eligibility rates from our previous work (Drucker et al, ASCO 2006). All costs are reported in 2007 Canadian dollars (CDN$). Results: aTZ had an upfront cost of CDN$49,965 per patient, but reductions in cancer recurrence over the 5-year analysis horizon reduced the net cost to CDN$44,998 per patient. Net impact declined over the initial 5 years (2007- 2011) as savings due to recurrences avoided accrued (start-up phase) and the ratio of net to gross annual budget impact fell from 95% to 85%. The cumulative net impact over the initial 5-year period (2007–2011) was roughly 10% less than the gross impact based on acquisition costs alone. In the second 5-year period (2012–2016), net and gross budget impact increased with population growth and increasing incidence in an ageing population (‘steady-state’ phase). Net budget impact in 2007 was projected to be CDN$91.3 million. Budget impact was driven primarily by the aTZ eligibility rate (8.5% in the baseline analysis). Conclusions: Annual net budget impact declined over the start- up phase as upfront costs were offset in part by savings due to recurrences avoided. Net budget impact in the steady-state phase grew at the same rate as the gross impact, but started from a lower baseline. While the projected net budget impact of aTZ was substantial, this analysis demonstrates the importance of accounting for differences in outcomes when conducting BIA. No significant financial relationships to disclose.